Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use KADCYLA safely and effectively. See full prescribing information for KADCYLA. KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: 2013
Medication labelWhy this: Advisory · dailymed-prescription
KADCYLA ® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-authorized test for KADCYLA [see Dosage and Administration (2.1) ]. KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment. Select patients for therapy based on an FDA-authorized test for KADCYLA [see Dosage and Administration (2.1) ].
- generic_name
- ado-trastuzumab emtansine
- product_names
- ADO-TRASTUZUMAB EMTANSINE
- ndc
- 50242-087, 50242-088, 50242-088-01, 50242-087-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en